2-氟-4-乙烯基吡啶 | 552331-57-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氟-4-乙烯基吡啶
• 英文名称: 2-fluoro-4-vinylpyridine
• 英文别名: 4-ethenyl-2-fluoropyridine
• CAS: 552331-57-4
• 化学式: C₇H₆FN
• mdl: MFCD11109695
• 分子量: 123.13
• InChiKey: WGVZHCAJTSCUEO-UHFFFAOYSA-N

物化性质

• 沸点：
  180.2±20.0 °C(Predicted)
• 密度：
  1.091±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P310,P330,P361,P403+P233,P405,P501
• 危险品运输编号：
  2810
• 危险性描述：
  H301,H311,H331

反应信息

• 作为反应物：
  描述：

  2-氟-4-乙烯基吡啶 在 palladium diacetate 、 三(邻甲基苯基)磷 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 8.0h， 生成 ((S)-1-(1H-Indol-3-ylmethyl)-2-{5-[(E)-2-(2-indol-1-yl-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation

  摘要：

  A novel series of Akt/PKB inhibitors derived from a screening lead (1) has been prepared. The novel trans-3,4'-bispyridinylethylenes described herein are potent inhibitors of Akt/PKB with IC50 values in the low double-digit nanomolar range against Akt1. Compound 2q shows excellent selectivity against distinct families of kinases such as tyrosine kinases and CAMK, and displays poor to modest selectivity against closely related kinases in the AGC and CMGC families. The cellular activities including inhibition of cell growth and phosphorylation of downstream target GSK3 are also described. The X-ray structure of compound 2q complexed with PKA in the ATP binding site was determined. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.017
• 作为产物：
  描述：

  2-氟吡啶 在 bis-triphenylphosphine-palladium(II) chloride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 2-氟-4-乙烯基吡啶
  参考文献：
  名称：

  Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation

  摘要：

  A novel series of Akt/PKB inhibitors derived from a screening lead (1) has been prepared. The novel trans-3,4'-bispyridinylethylenes described herein are potent inhibitors of Akt/PKB with IC50 values in the low double-digit nanomolar range against Akt1. Compound 2q shows excellent selectivity against distinct families of kinases such as tyrosine kinases and CAMK, and displays poor to modest selectivity against closely related kinases in the AGC and CMGC families. The cellular activities including inhibition of cell growth and phosphorylation of downstream target GSK3 are also described. The X-ray structure of compound 2q complexed with PKA in the ATP binding site was determined. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.017

文献信息

• Fe-Catalyzed Reductive Couplings of Terminal (Hetero)Aryl Alkenes and Alkyl Halides under Aqueous Micellar Conditions
  作者：Haobo Pang、Ye Wang、Fabrice Gallou、Bruce H. Lipshutz

  DOI：10.1021/jacs.9b04510

  日期：2019.10.30

  aromatic or heteroaromatic and an alkyl bromide or iodide leads, in the presence of Zn and a catalytic amount of an Fe(II) salt, to a net reductive coupling. The new C-C bond is regiospecifically formed at rt at the -site of the al-kene. The coupling only occurs in an aqueous micellar medium, where an atypical carbanionic, as opposed to radical, process is likely, supported by several control experiments

  在Zn和催化量的Fe(II)盐的存在下，乙烯基取代的芳族或杂芳族和烷基溴或碘的组合导致净还原偶联。新的 CC 键在 rt 在烯烃的  位点区域特异性地形成。偶联仅发生在水性胶束介质中，其中可能是非典型的碳负离子过程，而不是自由基过程，这得到了几个控制实验的支持。提出了一种基于这些数据的机制。
• Kinase inhibitors
  申请人：——

  公开号：US20030187026A1

  公开（公告）日：2003-10-02

  Compounds having the formula 1 are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

  具有以下化学式的化合物对抑制蛋白激酶很有用。还公开了抑制蛋白激酶的组合物以及在患者中抑制蛋白激酶的方法。
• Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：EP2085390A1

  公开（公告）日：2009-08-05

  The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen atom, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4)alkyl group or forms together with the group R1-Ar a ring fused with the Ar group, A represents a group of formula (β) or (δ):          -(CH2)t-     (β) R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or a group of formula (y):          -Y-Z-W-R11     (γ) wherein R11 represents an optionally labelled halogen atom, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen atom, a radionuclide, a -NO2 group, a -NR5R6 group, a -N+R5R6R7X- group, or a -OSO2R12 group, and their addition salts with pharmaceutically acceptable acids. The present invention also relates to pharmaceutical compositions comprising them and to their use in diagnosis, in particular with SPECT, PET and in therapy.

  本发明涉及以下式（I）的化合物： 其中 R1代表氢原子，可选择标记的卤原子，放射性核素或Sn[(C1-C4)烷基]3基团， Ar代表芳基团或杂芳基团， R9代表氢原子，(C1-C4)烷基团或与基团R1-Ar一起形成与Ar基团融合的环， A代表以下式（β）或（δ）的基团：          -(CH2)t-     (β) R3和R4独立地代表氢原子，(C1-C6)烷基团，(C1-C6)烯基团或以下式（γ）的基团：          -Y-Z-W-R11     (γ) 其中R11代表可选择标记的卤原子，放射性核素，芳基或杂芳基团，可选择地被可选择标记的卤原子，放射性核素，-NO2基团，-NR5R6基团，-N+R5R6R7X-基团或-OSO2R12基团取代，并且它们与药学上可接受的酸形成的加合盐。 本发明还涉及包含它们的药物组合物以及它们在诊断中的使用，特别是在单光子发射计算机断层扫描（SPECT）、正电子发射断层扫描（PET）和治疗中的使用。
• Ruthenium catalyzed β-selective alkylation of vinylpyridines with aldehydes/ketones <i>via</i> N₂H₄ mediated deoxygenative couplings
  作者：Leiyang Lv、Chao-Jun Li

  DOI：10.1039/d0sc06586b

  日期：——

  aldehyde/ketones via N2H4 mediated deoxygenative couplings. Compared with one-electron umpolung of carbonyls to alcohols, this two-electron umpolung strategy realized reductive deoxygenation targets, which were not only applicable to the regioselective alkylation of a broad range of 2/4-alkene substituted pyridines, but also amenable to challenging 3-vinyl and steric-embedded internal pyridines as well as their

  醛/酮的 Umpolung（极性反转）策略通过使用亲电试剂和脱氧官能化进行转化，极大地拓宽了羰基化学。在此，我们报道了第一次钌催化的乙烯基吡啶与天然丰富的芳香族和脂肪族醛/酮通过N 2 H 4进行的 β-选择性烷基化介导的脱氧偶联。与羰基到醇的单电子 umpolung 相比，这种双电子 umpolung 策略实现了还原脱氧目标，不仅适用于广泛的 2/4-烯烃取代的吡啶的区域选择性烷基化，而且还可以应对具有挑战性的 3 -乙烯基和空间嵌入的内部吡啶以及它们类似的杂环结构。
• 一种喹唑啉酮类化合物及其制备方法
  申请人：河北科技大学

  公开号：CN111116552B

  公开（公告）日：2022-10-11

  本发明涉及化学合成技术领域，具体公开一种喹唑啉酮类化合物及其制备方法。所述喹唑啉酮类化合物，其结构如式(Ⅰ)所示，其中，R1为氢、卤素、甲氧基、甲基、硝基或三氟甲基；R2为或R3为氢、卤素、甲氧基或甲基。本发明提供了一种新型结构的喹唑啉酮类化合物，丰富了喹唑啉酮类化合物的种类，为发展抗炎、抗肿瘤、抗惊厥或抗真菌药物提供了一种新化合物，对于研究该类化合物的活性以及扩大该类化合物在医学领域和工业生产上的应用具有十分重要的意义，为研究具有独特生理活性的新型药物提供了基础。